RLAY · All filings · Read this filing
What changed 10-Q
Item 5. Other Information
2022-11-03 compared with 2022-08-04 · 2 added, 5 removed, 35 unchanged (17% of the section changed)
Other Information
−Removed: As previously reported in our Current Report on Form 8-K filed with the SEC on May 27, 2022, in a non-binding advisory vote held at the 2022 Annual Meeting of Stockholders on the frequency of future say-on-pay votes regarding the compensation of our named executive officers, our stockholders expressed their preference for a say-on-pay vote to be conducted every one year.
−Removed: After taking into consideration the voting results and the prior recommendation of our board of directors in favor of an annual stockholder advisory vote on the compensation of our named executive officers, our board of directors intends to hold future advisory votes on the compensation of our named executive officers every year.
−Removed: Our board of directors will re-evaluate this determination after the next stockholder advisory vote on the frequency of say-on-pay votes (which will be at the 2028 Annual Meeting of Stockholders, unless presented earlier).
Fourth Amended and Restated Certificate of Incorporation of Relay Therapeutics, Inc.
25 unchanged sentences
RELAY THERAPEUTICS, INC.
−Removed: August 4, 2022
+Added: November 3, 2022
/S/ SANJIV K.
1 unchanged sentence
(Principal Executive Officer)
−Removed: August 4, 2022
+Added: November 3, 2022
/S/ THOMAS CATINAZZO
3 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.